Previous Close | 189.23 |
1-Year Change | 0.03% |
6-Months Change | 9.48% |
3-Months Change | -1.7% |
Moving Avg (50d) | 212.91 |
Moving Avg (200d) | 173.82 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 256.0B |
Beta (3-Years) | 1.19 |
Revenue Growth (ttm) | 76.38% |
Net Profit Margin (ttm) | -43.52% |
Return On Assets (ttm) | -17.37% |
EPS (ttm) | -0.72 |
PE Ratio (ttm) | -262.82 |
Dividend Yield | % |
Asset Description: | BeiGene, Ltd. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-16 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
198.145 | 203.973 | 207.858 | 213.686 | 223.399 | 233.112 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |